The FDA has approved the brand name for commercially available Veletri (epoprostenol for injection) for pulmonary arterial hypertension (PAH).
“Veletri is a proven therapy for the treatment of PAH patients who don’t respond adequately to conventional treatment, and rounds out a portfolio of therapies designed to address the diverse needs of patients with this chronic and life-threatening disease,” said Shal Jacobovitz, president of Actelion Pharmaceuticals US, Inc., which makes the product. Veletri has been commercially available since April 2010.
Veletri is an improved formulation of epoprostenol that offers greater convenience to patients than other formulations of the drug, according to an Actelion press release. Veletri is stable at room temperature for up to 24 hours when diluted as directed and placed into the pump for administration, eliminating the need for ice packs, the company stated.